Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 9 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 2024390317

    COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  2. US 12150777

    Treatment of depression

    United States Government as represented by the Department of Veterans Affairs · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  3. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  4. US 12144809

    Treatment of prostate cancer

    Takeda Pharmaceutical Company Limited · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  5. US 12146139

    Oligonucleotide interference treatments of prostate cancer

    The Board of Regents of the University of Oklahoma · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  6. US 12144801

    Methods and compositions for treatment of epileptic disorders

    OVID THERAPEUTICS INC. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  7. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  8. US 12138274

    Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  9. US 12139711

    Antisense oligonucleotides for the treatment of Leber congenital amaurosis

    Stichting Radboud universitair medisch centrum · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  10. US 12134767

    Materials and methods for treatment of hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  11. US 12134650

    Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  12. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  13. US 12128013

    Toxic aldehyde related diseases and treatment

    Aldeyra Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  14. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Vertex Pharmaceuticals Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  15. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  16. US 12128090

    Methods of prophylactic treatment using recombinant VWF (rVWF)

    Takeda Pharmaceutical Company Limited · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  17. US 12121288

    Combination tumor treatment

    Regents of the University of Minnesota · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  18. US 12121503

    Antiviral treatments

    BioCryst Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  19. US 12122998

    Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

    CRISPR THERAPEUTICS AG · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  20. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  21. US 12116405

    Arthritis treatment

    XBIOTECH INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  22. US 12115136

    Fortified CBD oil for treatment of PTSD

    Bright Green Corporation · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  23. US 12116574

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  24. US 12116589

    Treatment of amyotrophic lateral sclerosis (ALS)

    VOYAGER THERAPEUTICS, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted